Strategic Target Selection Focused on Niche Drug Development, and Strengthening
Corporate Governance to Advance Global Partnerships
[Mar 25, 2026] Calgent is dedicated to innovative drug development, today (Mar 25, 2026) officially announced the inauguration of its Operations and R&D Headquarters in New Taipei City. Positioned as a “globally market-driven niche drug development company”, Calgent’s core vision is to advance high-potential drug candidates to the global stage through cross-disciplinary integration and translational medicine. With the launch of its new headquarters, Calgent will further consolidate its R&D resources, enhance development efficiency, and strengthen overall innovation capabilities. Calgent also plans to initiate its initial public offering (IPO) in 2026. Through robust corporate governance and rigorous R&D management, Calgent aims to accelerate international strategic partnerships and expand its global footprint.
Business Model: Maximizing Asset Value through International Partnerships and Technology Licensing
Calgent adopts a flexible business model centered on “international partnerships and technology licensing”, with a focus on development programs addressing significant unmet medical needs and strong market potential. Through a dual-track approach of “in-house development” and “strategic in-licensing”, Calgent precisely defines the market positioning of its drug candidates and establishes efficient development and regulatory pathways. By engaging in early-stage communication and licensing collaborations with global pharmaceuticals, Calgent effectively mitigates development risks, shortens timeline to commercialization, and achieves the goals of drug launch and profit maximization.
Four Core Competitiveness: Key Drivers of Clinical Translation
Calgent has established a vertically integrated drug development platform anchored in three key strategies: “precise candidate selection”, “indication expansion”, and “value maximization”. Calgent’s four core competitiveness include:
- Innovative Drug Candidate Screening: Leveraging molecular modeling and AI technologies alongside a structured preclinical database to accurately focus on novel candidates with strong market potential.
- Pharmacology and Toxicology Validation: Equipping with rigorous, internationally compliant validation capabilities to ensure that R&D data meet global standards with high credibility and acceptance.
- Advanced Drug Formulation Technology Platforms: Owning distinctive integrated platforms covering poorly soluble small-molecule nano-oral formulations, transdermal delivery of peptide, polymer-based sustained-release systems, and specialized liposomal formulations. Platform may be optimized based on marketing needs to enhance bioavailability and therapeutic value.
- Clinical Translation Enhancement: Supporting by robust clinical trial design, and optimizing translational outcomes to significantly improve development efficiency and probability of success for drugs.
Strategic Focus: New Drugs in Oncology, Immunology & Inflammation, and Metabolic Diseases
Calgent is dedicated to developing precision therapies in the fields of oncology, immunology and inflammation, and metabolic diseases, aiming to significantly improve patient outcomes via innovative biotechnology solutions. Its R&D portfolio spans both small molecules and biologics (e.g. nanobodies), with several key programs achieving important milestones:
- Next-Generation Weight Management and Fat Reduction Therapy: The drug having an innovative mechanism of action targeting the obesity market, with preclinical animal data demonstrating fat-reduction efficacy comparable to Semaglutide, while offering clear differentiation by “preserving lean mass and slowing down weight rebound”- highlighting strong commercial potential.
- Anti-Inflammatory and Oncology Drugs: The oncology candidate has successfullycompleted Phase I clinical trials; the drug for idiopathic pulmonary fibrosis (IPF) is currently in Phase I trials; and the nanobody drug for inflammatory bowel disease (IBD) has entered process development, accelerating the IND-enabling studies.
Vision and Future: Strengthening Governance to Build a Foundation for Global Collaboration
Calgent views its planned 2026 IPO as a strategic milestone for long-term sustainable growth. By implementing best-in-class internal control systems, strengthening R&D management, and enhancing transparency in corporate governance, Calgent is building a solid foundation to engage with international capital markets and expand global partnerships. Looking ahead, Calgent will continue to advance drug candidates with strong global competitiveness, address unmet medical needs, and position itself as a rising innovator in the biotechnology and pharmaceutical industry.
